Lansoprazole
Product Images NDC 43598-561

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 43598-561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Lansoprazole 15 mg delayed-release orally disintegrating tablets packaging label. The label states the product strength (15 mg), dosage form (delayed-release orally disintegrating tablets), quantity (100 tablets, 10 packs of 10 tablets each), and distribution by Dr. Reddy's Laboratories, Inc. The label includes instructions for tablet removal from the blister and consumption, storage conditions, and phenylalanine content warning for phenylketonurics. The label bears the NDC number 43598-560-78 and a barcode.*

FDA Label Image

Carton2 (Carton2)

Carton packaging for Lansoprazole 30 mg delayed-release orally disintegrating tablets by Dr. Reddy's Laboratories Inc. The label indicates 100 tablets, packaged as 10 packs of 10 tablets each. It includes pharmacist instructions to dispense a medication guide, storage instructions, and illustrated directions for tablet removal and administration. The product is made in India.*

FDA Label Image

Figure1 (Figure1)

A line graph showing mean severity of day heartburn by study day for evaluable patients, comparing placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily. The severity scale ranges from 0 (None) to 3 (Severe), plotted against days from the start of treatment.*

FDA Label Image

Figure2 (Figure2)

Line graph showing the mean severity of night heartburn over approximately 60 days from treatment start. The graph compares placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily, with severity rated from 0 (none) to 3 (severe). The Lansoprazole groups show a rapid decrease in heartburn severity compared to placebo.*

FDA Label Image

Logo (Logo)

Chemical structure diagram of lansoprazole, illustrating the molecular arrangement of the active ingredient lansoprazole. The diagram shows the chemical bonds and ring structures characteristic of this compound.*

FDA Label Image

Structure (Structure)

Chemical structure of Lansoprazole showing the molecular arrangement including a benzimidazole ring, a sulfinyl group, and a substituted pyridine ring with trifluoromethoxy and methyl groups, as typically represented in pharmaceutical chemistry.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.